Browse Category

NYSE:PFE 3 January 2026 - 18 January 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer Inc shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters.

18 January 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week.

17 January 2026

Earnings·NYSE:JNJ·NYSE:LLY·NYSE:MRK·NYSE:NVO·NYSE:PFE·NYSE:UNH

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Shares of Pfizer Inc closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight.

17 January 2026

NASDAQ:ABUS·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates

Pfizer shares slipped 0.9% to close at $25.65 on Friday, just ahead of the U.S. market’s long weekend. Trading volume hit roughly 58 million shares.

17 January 2026

Earnings Reports·NYSE:PFE·Pfizer News·Stock Market

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands.

15 January 2026

NASDAQ:GPCR·NYSE:PFE·NYSE:SNY·Pharmaceuticals·Stock Market

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.

15 January 2026

NASDAQ:GP·NASDAQ:MRNA·NYSE:LLY·NYSE:MRK·NYSE:NVO·NYSE:PFE·NYSE:SNY·Pharmaceuticals·Stock Market

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Shares of Pfizer climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector.

15 January 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials for its Metsera obesity compounds by the end of 2026, aiming to fuel future growth. The company still doesn’t expect revenue growth to return until 2029, as it navigates patent expirations and a slowdown in COVID-era sales.

14 January 2026

Earnings Reports·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.

14 January 2026

Earnings Reports·NYSE:LLY·NYSE:NVO·NYSE:PFE·Pharmaceuticals·Stock Market

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%.

14 January 2026

Earnings Reports·NYSE:ABBV·NYSE:JNJ·NYSE:MRK·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session.

13 January 2026

Earnings Reports·NYSE:PFE·Pfizer·Pharmaceutical Industry

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.

13 January 2026

NASDAQ:VKTX·NYSE:NVO·NYSE:PFE·Pfizer·Pharmaceuticals

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27.

13 January 2026

NYSE:NVO·NYSE:PFE·Pharmaceuticals·Stock Market

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday's premarket session.

12 January 2026

NYSE:AZN·NYSE:BMY·NYSE:GSK·NYSE:MRK·NYSE:NVS·NYSE:PFE·Stock Market

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27.

12 January 2026

Artificial Intelligence·Earnings Reports·NYSE:AZN·NYSE:MRK·NYSE:NVS·NYSE:PFE·Stock Market·Technology

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters

8 January 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS.

7 January 2026

Biotechnology·NASDAQ:BNTX·NASDAQ:MRNA·NYSE:PFE·XETRA:BAYN

Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17. Pfizer

6 January 2026

NYSE:PFE·Pharmaceuticals·Stock Market

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high.

6 January 2026

NASDAQ:AMGN·NYSE:ABBV·NYSE:JNJ·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer Inc shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday.

3 January 2026

Earnings Reports·NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Previous 1 … 3 4 5 6 7 … 12 Next

NYSE:PFE 3 January 2026 - 18 January 2026

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

TechStock² Updates

Berkshire Hathaway’s $7.8 Billion Repurchase Strategy Puts Greg Abel to the Test on Monday

Airbnb (NASDAQ:ABNB) Rallies 17% With AI Savings Sending Stock Past Wall Street Target

DoubleVerify (NYSE:DV) faces 3% remaining upside as deal with Nielsen pushes expected close to 2027

Bob’s Discount Furniture (NYSE:BOBS) meets 11.4% margin challenge in H2

The Trade Desk (NASDAQ:TTD) Drops 21.9% as Q3 Outlook Points to 25% Adjusted EBITDA Margin

Top Stock Picks

AerCap

Constellation Energy

Cheniere Energy

Walt Disney

AIG

Live updates

Investment Disclaimer